182 related articles for article (PubMed ID: 25702261)
1. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Clancy C; Burke JP; Coffey JC
Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
[TBL] [Abstract][Full Text] [Related]
3. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
4. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
[TBL] [Abstract][Full Text] [Related]
5. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
[TBL] [Abstract][Full Text] [Related]
8. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
9. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
[TBL] [Abstract][Full Text] [Related]
11. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
12. Complete response after neoadjuvant therapy in rectal cancer: to operate or not to operate?
Dedemadi G; Wexner SD
Dig Dis; 2012; 30 Suppl 2():109-17. PubMed ID: 23207942
[TBL] [Abstract][Full Text] [Related]
13. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.
Renaud S; Schaeffer M; Falcoz PE; Seitlinger J; Romain B; Voegeli AC; Legrain M; Reeb J; Santelmo N; Rohr S; Brigand C; Olland A; Guenot D; Massard G
Eur J Cardiothorac Surg; 2017 Feb; 51(2):255-262. PubMed ID: 28186237
[TBL] [Abstract][Full Text] [Related]
14.
Sideris M; Moorhead J; Diaz-Cano S; Haji A; Papagrigoriadis S
Anticancer Res; 2017 Mar; 37(3):1349-1357. PubMed ID: 28314302
[TBL] [Abstract][Full Text] [Related]
15. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.
Abdul-Jalil KI; Sheehan KM; Toomey S; Schmid J; Prehn J; O'Grady A; Cummins R; O'Neill B; McNamara DA; Deasy J; Breathnach O; Grogan L; Rogers A; Doherty G; Winter D; Ryan J; El-Masry S; Gibbons D; Sheahan K; Gillen P; Kay EW; Hennessy BT
Ann Surg Oncol; 2014 Aug; 21(8):2642-9. PubMed ID: 24700299
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.
Peng J; Lv J; Peng J
Int J Colorectal Dis; 2021 Aug; 36(8):1781-1790. PubMed ID: 33760952
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
El Otmani I; El Agy F; El Baradai S; Bouguenouch L; Lahmidani N; El Abkari M; Benajah DA; Toughrai I; El Bouhaddouti H; Mouaqit O; Ibn Majdoub Hassani K; Mazaz K; Benjelloun EB; Ousadden A; El Rhazi K; Bouhafa T; Benbrahim Z; Ouldim K; Ibrahimi SA; Ait Taleb K; Chbani L
Dis Markers; 2020; 2020():8459303. PubMed ID: 31998419
[TBL] [Abstract][Full Text] [Related]
18. Instrumental clinical restaging, pathological evaluation, and tumor regression grading: how to assess the response to neoadjuvant chemoradiotherapy for rectal cancer.
Benzoni E; Terrosu G; Intersimone D; Milan E; Chiaulon G; Bresadola V; Sacco C; Sattin E; Bresadola F; Avellini C
Int J Colorectal Dis; 2007 Jan; 22(1):7-13. PubMed ID: 16538492
[TBL] [Abstract][Full Text] [Related]
19. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Chen Z; Duldulao MP; Li W; Lee W; Kim J; Garcia-Aguilar J
J Am Coll Surg; 2011 Jun; 212(6):1008-1017.e1. PubMed ID: 21458303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]